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ReviewHistone deacetylase 8 (HDAC8) is a class I histone dea-
cetylase implicated as a therapeutic target in various
diseases, including cancer, X-linked intellectual disabili-
ty, and parasitic infections. It is a structurally well-char-
acterized enzyme that also deacetylates nonhistone
proteins. In cancer, HDAC8 is a major ‘epigenetic player’
that is linked to deregulated expression or interaction
with transcription factors critical to tumorigenesis. In
the parasite Schistosoma mansoni and in viral infec-
tions, HDAC8 is a novel target to subdue infection.
The current challenge remains in the development of
potent selective inhibitors that would specifically target
HDAC8 with fewer adverse effects compared with pan-
HDAC inhibitors. Here, we review HDAC8 as a drug
target and discuss inhibitors with respect to their struc-
tural features and therapeutic interventions.
HDAC8: a unique class 1 deacetylase
HDACs are ‘eraser’ enzymes that cleave acetate from
acetylated e-amino groups of lysines in histones and other
proteins. Deacetylation of histones causes global chroma-
tin condensation and transcription repression [1]. HDACs
participate in critical signaling networks and their de-
regulation has been linked to many diseases [2], includ-
ing cancer, neurodegenerative disorders, metabolic
dysregulation, and autoimmune and inflammatory dis-
eases; hence, HDACs continue to be interesting drug
targets [3].
While most disease-oriented research has focused on
HDAC 1–3 and 6 [4], lately there has been an increasing
interest in the isotype HDAC8 as a drug target [5]. This is a
zinc-dependent class I HDAC containing 377 amino acids
(aa, 42 kDa) [6–8] that is ubiquitously expressed and that0165-6147/
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schistosoma; X-ray crystallography.can localize to either the nucleus (primary site) or the
cytoplasm [6–9]. HDAC8 diverged from other class I
enzymes early in evolution, indicating a discrete functional
specialization [10]. It is X-linked in humans, and its activi-
ty is independent of additional co-factors [6–8]. The C-
terminal (aa 50–111) protein-binding domain of other
HDACs is not present in HDAC8 [11]. The L1 loop in
the proximity of the active site is highly flexible and can
undergo conformational changes to accommodate different
substrates [11]. The presence of serine 39 phosphorylation
near the active site is special to HDAC8 and negatively
regulates its activity [11,12]. Some unique nonhistone
proteins [13–15], such as cohesin, estrogen receptor a
(ERRa), or cortical actin-binding protein (cortactin), have
been linked with HDAC8. Thus, it controls diverse pro-
cesses, such as sister chromatid separation, energy homeo-
stasis, microtubule integrity, and muscle contraction
[9,13,14]. Consequently, it is not surprising that HDAC8
has a multifaceted role in human pathophysiology. Muta-
tions leading to changes in its structure and activity are
reported in Cornelia de Lange syndrome (CdLS) [16]. In
cancer, HDAC8 is either deregulated, overexpressed, or is
reported to interact with transcription factors [17–
20]. Moreover, HDAC8 is correlated with childhood neu-
roblastoma and T cell lymphoma [21–23]. In parasitic and
viral infections, HDAC8 inhibition leads to reduced infec-
tion [24,25]. Here, we review the evidence of the crucial
importance of HDAC8 in many diseases, present available
inhibitors with a focus on the structural basis of inhibition,
and highlight the potential for therapeutic intervention by
HDAC8 inhibition.
HDAC8 substrates
Although both core histones (preferentially H3 and H4)
and histone-tail derived peptides are known to be deace-
tylated in vitro [6,7,12], histones remain controversial in
vivo as bona fide HDAC8 substrates. While deacetylation
occurs specifically at acetylated lysines (Kac) 14, 16, and
20 on histone H4-derived peptides [6,8,26] (Figure 1), manyTrends in Pharmacological Sciences, July 2015, Vol. 36, No. 7 481
Glossary
AT-rich interactive domain-containing protein 1A (ARID1A): encoded by the
ARID1A gene. ARID1A is a transcription factor, a part of the switch/sucrose
nonfermentable (SNF/SWI) chromatin-remodeling complex, and is thought to
recruit the complex to DNA to activate transcription of repressed genes. The
protein contains two domains: a DNA-binding domain that binds AT-rich
sequences of the DNA, and the C terminus, which can activate transcription in a
glucocorticoid-dependent fashion. The gene is mutated in many cancers and
the protein functions as a tumor suppressor.
Cortical actin-binding protein (cortactin): acts as a regulator of actin dynamics
and promotes actin polymerization. F-actin interacts with cortactin on a special
repeat region. Acetylation of nine lysine residues in this repeat region inhibits
F-actin interaction, while deacetylation promotes F-actin binding and positively
regulates actin dynamics by promoting polymerization.
c-AMP response element-binding protein (CREB): a transcription factor that
binds specifically to c-AMP response elements in DNA and regulates genes
such as those encoding somatostatin and c-fos. It is activated by phosphoryla-
tion by protein kinase A and is involved in the maintenance of circadian rhythm
and in Huntington’s disease. This protein can be deactivated by phosphatases,
such as PP1, which is a serine threonine phosphatase.
Differentiated embryo-chondrocyte expressed gene 1 (DEC1): a basic helix-
loop-helix transcription factor that acts as a transcriptional repressor by
recruiting HDACs as a co-repressor. It can transactivate several genes, such as
that encoding survivin. It is a target of the p53 family of proteins and modulates
their activity. Functionally, DEC1 is important in circadian rhythm, senescence,
cellular differentiation, and apoptosis. Upregulation of DEC-1 has been
associated with gastric cancer.
Estrogen receptor a (ERRa): encoded by the gene ESR1. It is a nuclear receptor
activated by estrogen and overexpressed in estrogen-associated cancers, such
as breast cancer.
Inv(16) fusion protein: a product of the most frequent chromosomal
translocation in AML-1. It fuses core binding factor b with smooth muscle
myosin heavy chain, resulting in an oncogenic chimeric protein. This
translocation disrupts AML-1 function. The C-terminal assembly complex
domain of the smooth muscle myosin heavy chain region can associate with
co-repressors, such as HDAC8, and repress transcription.
Nuclear receptor co-activator 3 (NCOA3): encoded by NCOA3 gene and
belongs to the SRC-1 family of transcriptional coactivators. The protein has an
intrinsic acetyltransferase activity and can acetylate histones to enhance
transcription. NCOA3 protein increases nuclear receptor transcription. Over-
expression and gene amplification of NCOA3 has been associated with
estrogen receptor-positive breast and ovarian cancers.
Retinoic acid induced 1 (RAI1): encoded by the RAI1 gene. The protein is a
transcription factor. It may be a part of a complex and acts as a transactivator.
RAI1 is associated with neuronal disorders, such as Smith–Magenis syndrome.
Suppressor of cytokine signaling 1/3 (SOCS1/3): cytokine-induced negative
regulators of cytokines that act by inhibiting the JAK/STAT pathway. They are
also known to inhibit inflammatory responses in macrophages and microglia.
Overexpression of these proteins is associated with breast cancer.
TAp73: an isoform of P73, a member of the p53 family. It is transcribed from the
upstream P1 promoter and the protein acts as a regulator of p53 target genes. It
is a tumor suppressor with additional functions in innate immunity and septic
shock. It is often overexpressed in cancer and is associated with enhancement
of the pentose phosphate pathway, as well as with proliferation in tumors.
Thyroid hormone receptor-associated protein 3 (THRAP3): encoded by the
THRAP3 gene. It is a transcription factor associated with RNA splicing and
degradation. It has a crucial role in diabetes gene programming and can also
regulate DNA damage.
Zinc finger Ran-binding domain-containing protein 2 (ZRANB2): encoded by
the ZRANB2 gene. It is part of a supraspliceosome and acts as a splicing factor
of many genes, several of which are involved in cancer development. It is
upregulated in grade III ovarian serous papillary carcinoma.
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histones as in vivo substrates of HDAC8 [15,27]. Initially,
overexpression studies with HDAC8 showing lower levels
of acetylated H3 and H4 in cells indicated histones as
classical substrates [7,12]; however, inactivity in HDAC8
immunoprecipitated with an acetylated H4 peptide has
been also reported [7]. Current data on the absence of
global histone H3 hyperacetylation in HDAC8-specific in-
hibitor treated cells additionally suggest that HDAC8 has
other major cellular substrates [7,23] and prefers specific
gene regions in histones (H3) for deacetylation, as shown
by ChIP experiments [28].482The controversies between in vitro and in vivo status of
histones may arise from several caveats. While overexpres-
sion may change the normal deacetylase activity, multiple
washing in immunoprecipitation might wash away the
substrate (if loosely associated) or might have other
HDACs as contaminants (due to >30% similarity in aa
sequences of class I HDACs [29,30]). Additionally, global
acetylation modifications in histones might mask the spe-
cific deacetylation pattern of H3 by HDAC8. Moreover,
given that other HDACs also act on histones, a counter
regulation may conceal the effect. Hence, cell-based inhi-
bition approaches combined with mass spectrometry are
emerging as alternative methods to identify ‘in cellulo’
substrates of HDAC8 [15]. Thus, histones cannot be called
general bona fide substrates of HDAC8, but there is evi-
dence that some histone hyperacetylation is observed upon
HDAC8 inhibitor treatment [27].
A quest for further substrates identified multiple part-
ners, including structural maintenance of chromosomes 3
(SMC3), p53, ERRa, and inv(16) fusion protein [13,14,
31,32] (Figure 1; see Glossary). The latest additions are
retinoic acid induced 1 (RAI1), zinc finger, RAN-binding
domain containing 2 (ZRANB2), nuclear receptor co-acti-
vator 3 (NCOA3), thyroid hormone receptor-associated
protein 3 (THRAP3), AT-rich interactive domain-contain-
ing protein 1A (ARID1A), and cortactin [9,15]. These pro-
teins have diverse physiological functions, from regulation
of the cell cycle, carcinogenesis, to muscle contraction,
indicating an intricate role of HDAC8 in cellular homeo-
stasis. While direct deacetylation occurs in some of these
proteins, such as SMC3, HDAC8 may act as a scaffold for
other candidates and recruit these proteins in complexes. A
special example could be the inv(16) fusion protein, where
HDAC8 might act both as a deacetylase and an interacting
scaffold [32]. As a scaffolding protein, association between
HDAC8 and cAMP responsive element binding protein
(CREB) provides an alternative example [33]. Both protein
phosphatase 1 (PP1) and CREB co-precipitate with
HDAC8; overexpression of HDAC8 decreases CREB phos-
phorylation as well as its activity, suggesting HDAC8 as a
scaffolding platform for increased interaction of PP1 phos-
phatase and CREB [33]. It is difficult to differentiate the
deacetylation versus scaffolding functions of HDAC8 in
vivo, because the enzyme–substrate interactions might
be short lived. While knockout or knockdown of HDAC8
could provide a mechanistic clue, such experiments would
not present direct proof of enzyme association or activity
(global deletion of HDAC8 in mice after birth is not lethal
[34]). Catalytic dead mutants in cellular contexts might
add more insight to distinguish between deacetylation and
scaffolding roles of HDAC8.
Interestingly, in some of the proteins mentioned above,
HDAC8 exhibits selectivity for certain deacetylation sites.
Distinct motifs, such as arginine-Kac129 (RKac) in ERRa,
RSKacFE in inv(16) fusion protein, and RHKK in p53 are
shown to be preferred by HDAC8 [13,35,36] (Figure 1). A
similar KRHR motif in H4 is also deacetylated by HDAC8
[37]. In general, an N-terminal arginine at position -1 to
the Kac and an aromatic ring (e.g., phenylalanine) at the C-
terminal position +1 constitute the most effective deace-
tylation sites [35,38]. Serine at -1 usually diminishes this
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Figure 1. Protein deacetylation and substrates of histone deactylase 8 (HDAC8). In vitro, HDAC8 can deacetylate both histone [6–8,12] and nonhistone substrates, such as a
tetrapeptide derived from p53 [39]. In vivo, nonhistone proteins seem to be major deacetylation substrates [9,13–15,31,32], while histones remain controversial as bona fide
substrates of HDAC8. Representative nuclear and cytoplasmic nonhistone substrates are shown here. RKac and RSKacFE are specific motifs associated with HDAC8.
Abbreviations: Kac, acetylated lysine; RKac, arginine at 1 position to Kac; RSKacFE, arginine-serine-Kac-phenyl-glutamic acid.
Review Trends in Pharmacological Sciences July 2015, Vol. 36, No. 7preference [35]. Furthermore, the presence of a conserved
Asp101 in the rim of the active site is also known to
critically contribute to substrate positioning (in a cis con-
formation) [39].
In in vitro screening, trifluoracetylated substrates have
often been used to boost deacetylation rates [40,41], but
acetylated tetrapeptides with a C-terminal fluorophore
also work [39]. It has been shown that, in many cases,
IC50 values are very similar but may differ with different
substrates by up to 20-fold in potency for certain inhibitors
[42].
HDAC8 and diseases
Cancer
HDAC8 is expressed in a variety of adult cancer tissues,
such as colon, breast, lung, and pancreas, as well as in
childhood cancer tissues, such as neuroblastoma
[43,44]. The level is similar in cancer and corresponding
healthy tissues, with a tendency towards higher expression
in cancer tissues [31,43]. Knockdown of HDAC8 by RNA
interference (RNAi) inhibits proliferation of human lung,
colon, and cervical cancer cell lines (Figure 2), and the
upregulation of HDAC8 promotes proliferation and inhi-
bits apoptosis in hepatocellular carcinoma [31,45].
Microarray analyses of adult T cell leukemia/lymphoma
(ATL) revealed that HDAC8 expression in these tumor
cells is regulated by the transcription factor SRY (sex
determining region Y)-box 4 (SOX4) [46–48], which directly
activates the HDAC8 promoter [49] (Figure 2). HDAC8
knockdown suppresses growth of ATL cell lines [49] and
the treatment of T cell-derived lymphoma and leukemic
cells (e.g., Jurkat, HuT78, and Molt-4) with the HDAC8
specific inhibitor PCI-34051 induces calcium-mediated and
caspase-dependent apoptosis [23] (Figure 2). However,
solid cancer cell lines, such as A549 (lung), RKO (colon),
U87 (glioma), and MCF-7 (breast), do not respond to such
treatment with apoptosis [23]. Nevertheless, HDAC8 is
among the HDAC family members that are upregulated ininvasive breast tumor cells and the enforced overexpres-
sion of HDAC1, 6, or 8 supports invasion and matrix
metallopeptidase 9 (MMP-9) expression of MCF-7 breast
cancer cells [18].
In normal development, HDAC8 controls patterning of
the skull in cranial neural crest cells of mice. Consequent-
ly, deletion of HDAC8 in mice leads to perinatal (P1)
lethality due to skull instability [34]. In neural crest-de-
rived neuroblastoma, HDAC8 expression correlates with
advanced tumor stage and poor outcome, and selective
inhibition induces differentiation, shown by the outgrowth
of neurite-like structures [44]. HDAC8 inhibitors showed
advantages over pan-HDAC inhibition with regard to tox-
icity and efficacy in a preclinical neuroblastoma model
[21,50,51]. Targeting of other HDAC isotypes in neuroblas-
toma results in completely different phenotypes (apoptosis
or blocked autophagy) [52–54].
Mechanistically, HDAC8 has been shown to affect telo-
merase activity by protecting the human ever-shorter
telomeres 1B (hEST1B) protein against ubiquitin-mediat-
ed degradation, a function dependent on the phosphoryla-
tion status of HDAC8 [55]. HDAC8 also associates with the
inv(16) fusion protein and other co-repressors to repress
acute myeloid leukemia-1 (AML-1)-regulated genes (such
as p21), which might result in abnormal hematopoietic cell
proliferation, as seen in leukemia [32,56]. Furthermore,
HDAC8 cooperates with the transcription factor differen-
tiated embryo-chondrocyte expressed gene 1 (DEC1) to
enhance TAp73 expression, thus differentially controlling
this tumor suppressor [20]. HDAC8 also downregulates
suppressor of cytokine signaling 1/3 (SOCS1/3) expression,
altering Janus kinase 2/signal transducer and activator of
transcription (JAK2/STAT) signaling; inhibition of HDAC8
led to SOCS1/3-dependent reduction in cell growth and
clonogenic activity of hematopoietic cells derived from
patients with myeloproliferative neoplasms [57,58]. Addi-
tionally, HDAC8 mediated regulation of Bcl-2-modifying
factor (BMF) via cooperation with STAT3 has also been483
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Figure 2. Overview of selected biological roles of histone deactylase 8 (HDAC8). Human HDAC8 is associated with: (A) cancer [19,20,23,31,32,44,49,55,57–59]; (B) muscle
contraction [9]; and (C) entry of viruses [25]. (A) Representative molecular interactions of HDAC8 with crucial proteins in cancer. (i) Induction of HDAC8 expression by SOX4,
a direct target gene of FRA2/JUND [49]. (ii) HDAC8 associates with co-repressors, such as mSin3A and, AML-1, represses AML regulatory genes, and affects hematopoietic
cell proliferation [32]. (iii) Phosphorylated HDAC8 protects hEST1B from ubiquitin-mediated degradation affecting total telomerase activity. As a result, telomeres escape
shortening and, consequently, cells escape senescence [55]. (iv) HDAC8 associates with DEC1 to upregulate Tap73 expression and control the balance of this tumor
suppressor [20]. (v) HDAC8 represses SOCS1/3 expression, which in turn enhances JAK2/STAT expression and cell growth [58]. (vi) HDAC8 interacts with STAT3 to repress
BMF transcription [59]. (vii) HDAC8 regulates HOXA5 gene transcription to control p53 expression [19]. (viii) Inhibition of HDAC8 by siRNA or inhibitors leads to cell death,
apoptosis, and differentiation of cells. (B) Upon contractile stimulation, HDAC8 deacetylates cortactin to promote actin polymerization and smooth muscle contraction [9].
(C) HDAC8 is associated with enhanced endocytosis of late-penetrating viruses by controlling acidification of vesicles and microtubule integrity in host cells, concurrent
with increased infection [25]. Abbreviations: HDAC8i, HDAC8 knocked down or inhibited by inhibitors; PKA, protein kinase A. For additional definitions, please see the main
text.
Review Trends in Pharmacological Sciences July 2015, Vol. 36, No. 7reported [59] (Figure 2). BMF has an important function in
the execution of apoptosis triggered by the metabolite
methylselenopyruvate, which is an inhibitor of HDAC8
[60]. Another important mechanistic pathway demon-
strates a link between HDAC8 and the tumor suppressor
p53 [19,31] (Figure 2). Depletion of HDAC8 decreased
homeobox A5 (HoxA5)-dependent expression of wild type
(WT) and mutant p53 [19]. HDAC8 is required for the
expression of p53, regardless of whether it is WT or mu-
tated. However, depletion or inhibition of HDAC8 only
affects proliferation of those cells harboring a p53 muta-
tion. This suggests that HDAC8 inhibitors are reasonable
as an adjuvant for tumors carrying a mutant p53. Inter-
estingly, although co-localization studies with ChIP [20] or
overexpression and/or siRNA knockdowns showed associ-
ation of these proteins with HDAC8, it remains unresolved
whether they are direct deacetylation targets. It is tempt-
ing to speculate that HDAC8 provides a scaffolding plat-
form for signaling complexes that ferry inside the nucleus
to act on specific loci of DNA, affecting expression of
particular genes critical to cancer.
Schistosomiasis
Besides cancer, HDAC8 has been lately discovered as an
important target to fight the ‘neglected’ parasitic disease
schistosomiasis [24] (Figure 3). This is a parasitic infection484caused by Schistosoma flatworms that affects over 200 mil-
lion people [61]. Severe symptoms stem from the reaction
of the body to chronic exposure to rejected eggs [62]. Control
depends on the administration of a single drug, praziquan-
tel, which poses a threat of resistance [63,64]. Moreover,
praziquantel is ineffective towards immature worms, thus
enabling the persistence of the infection [64], which adds to
the need of new approaches in drug treatment.
The sequencing and annotation of the genomes of para-
sites has allowed new approaches to drug development,
including the targeting of epigenetic processes. This is
especially true for HDACs, which, as already mentioned,
have been exploited for drug development in other pathol-
ogies, notably cancer [65,66]. Death of schistosome larvae
and adult worms in culture via the induction of apoptosis
after treatment with trichostatin A (TSA), a pan-inhibitor
of HDACs, indicated HDAC targeting as a possible strate-
gy in schistosomes for drug development [67].
Schistosomes have three class I and three class II
HDACs [68], among which HDAC8 (smHDAC8 in Schis-
tosoma mansoni) is the least conserved compared with its
human ortholog, exhibiting amino acid substitutions and
insertions in the catalytic pocket [68,69]. smHDAC8 is the
most abundant class I transcript, being expressed at high
levels during almost all stages of the life cycle [69]. Tran-
script knockdown of smHDAC8 using RNAi in invasive
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Figure 3. Schistosome targets of Schistosoma mansoni histone deactylase 8 (smHDAC8) inhibitors. Human hosts are infected by free-living cercariae (A), which lose their
tails to become schistosomula (B). These larvae migrate within the host bloodstream, mature in the hepatoportal system, and form pairs of male and female worms (C),
which then localize to the mesenteric veins (in the case of S. mansoni), where female worms lay hundreds of eggs (D) daily. A proportion of these eggs circulates and
becomes trapped in the capillary system, particularly in the liver, where they provoke an inflammatory granulomatous reaction (E), responsible for disease pathology. The
administration of smHDAC8 inhibitors (smHDAC8i) in culture affects both schistosomula, causing apoptosis and death [(F) pink TUNEL staining], and adult worms, causing
marked changes in the reproductive organs, separation of worm pairs (G) and arrest of egg laying [24]. Life-cycle stages in the fresh-water snail intermediate host are not
shown.
Review Trends in Pharmacological Sciences July 2015, Vol. 36, No. 7schistosome larvae (schistosomula) significantly reduced
the recovery of adult worms and eggs from infected mice,
and chemical inhibition induced unpairing of adult worms,
demonstrating the validity of the target [24] (Figure 3).
Other diseases
Viral infections. A prominent role of HDAC8 has been
deciphered recently in Influenza A and Uukuniemi virus
entry [25]. These late-penetrating viruses use endocytosis
to enter host cells, and this is followed by aci-activated
penetration from late endosomes [25,70]. HDAC8 (and
HDAC3) is associated in vitro with enhanced endocytosis,
acidification, and penetration of these viruses (Figure 2),
while HDAC1 produces the opposite results. Downregula-
tion of HDAC8/HDAC3 by siRNA showed a reduction in
viral infectivity [25]. This involved the pathway from early
endosomes to lysosomes, resulting in ineffective endocy-
tosis and insufficient acid conversion of the viruses
[25]. Depletion of HDAC8 evokes rearrangement of the
microtubule network, causing centrosome splitting, loss of
centrosome-associated microtubules, and disorientation
of centripetal movements of late endosomes and/or lyso-
somes. Thus, HDAC8 is critical to centrosome architecture
and cohesion that controls endosome mobility. However, it
remains obscure whether deacetylation of the centrosome
itself, of microtubules, or of regulators of centrosome
cohesion influences viral entry.CdLS. HDAC8 is one of the causative genes in CdLS, (a
rare genetic disease causing congenital malformations)
and has been identified as the SMC3 deacetylase
[14,71,72]. SMC3 is a cohesin subunit that binds sister
chromatids together [73]. HDAC8 deacetylates chroma-
tin-released acetylated SMC3 in early mitosis, facilitat-
ing cohesin recycling for subsequent cell cycles [14]. Lack
of HDAC8 activity induces an accumulation of acetylated
cohesins with reduced affinity towards chromatids and
subsequently leads to defective transcription with clini-
cal symptoms as seen in CdLS [14]. Loss-of-function
HDAC8 mutations, mainly in conserved residues [74],
are predominantly missense, occur mostly de novo, are
associated with severely skewed X inactivation, and
show strong loss of activity [16]. One hundred percent
inactive mutants demonstrate major structural changes
within the catalytic active site or in the surrounding
residues [16]. It has been proposed that the loss of
HDAC8 activity correlates with the proximity of the
mutated residues to the active site [74]. The activity
of most mutants is restored by a specific activator of
HDAC8, N-(phenylcarbamothioyl)benzamide, except
where the mutation is closest to the active site, tempting
the authors to speculate that the activator might stabi-
lize the enzyme conformation for substrate binding,
which is not possible when the mutation is close to
the active site [74].485
Review Trends in Pharmacological Sciences July 2015, Vol. 36, No. 7Structural aspects and inhibitors of HDAC8
Selective HDAC8 inhibitors (HDAC8i) with characteriza-
tion in advanced preclinical models are still scarce. Exam-
ples are several benzhydroxamates (Figure 4A, Table 1),
such as the ‘linkerless’ inhibitor 1, compound 2, the 12-
membered macrocycle-based phenyl hydroxamate 3, andN
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23,75–82]. (B) Inhibitors co-crystalized with HDAC8 [11,24,39,45,74,82,87,96–98].
Table 1. IC50 values of HDAC8i against class I and class II HDACs
a
Compound Class I HDACs Class II HDACs Refs
HDAC1 HDAC2 HDAC3 HDAC8 smHDAC8 HDAC4 HDAC6
1 >100 mM – – 0.3 mM – – 55 mM [75]
2 12 mM 9 mM 23 mM 0.12 mM – >33 mM 0.036 mM [76]
3 – 3.6 mM 15 mM 0.023 mM – -– – [77]
4 4.5 mM >20 mM 4.8 mM 5.7 nM – >20 mM >20 mM [79]
5 38 mM >100 mM 68 mM 0.070 mM – 44 mM 2.4 mM [78]
6 >100 mM >100 mM >100 mM 0.053 mM – >100 mM 2.2 mM [78]
7 4 mM >50 mM >50 mM 0.01 mM – – 2.9 mM [23]
8 >1000 mM >1000 mM >1000 mM 4.53 mM – >1000 mM >1000 mM [80]
9 nia – nia 0.5 mM – – – [81]
10 >30 mM >30 mM – 200 nM – – >30 mM [82]
J1038 23.6 mM – 12.3 mM 0.97 mM 1.48 mM – 3.5 mM [24]
J1075 19.4 mM – 1.9 mM 3.1 mM 4.32 mM – 37.4 mM [24]
(1a) – – – 200 mM 50 mM – – [87]
SAHA 117 nM – 123.8 nM 0.4 mM 1.6 mM – 72.9 nM [24,87]
M344 43.1 nM – 17.62 nM 2.9 mM 2.4 mM – 81.6 nM [24,87]
aAbbreviations: ni, no inhibition; –, values not reported.
Review Trends in Pharmacological Sciences July 2015, Vol. 36, No. 7antiproliferative effects towards several human lung
cancer cell lines [79]. The indole PCI34051 (7) is also
a nanomolar and highly selective inhibitor (> 200-fold
compared with other HDACs). It exhibited limited cellu-
lar activity in T cell leukemia cells and no activity in
other tumor cells [23,79] (Figure 4A). Other chemical
classes include the azetidinone 8, the cyclic thiourea SB-
379278A (9), and the amino acid derivative 10 [80–
82]. Compounds 1, 8, and 9 show moderate HDAC8
selectivity (not tested for all HDAC isoforms) and inhibi-
tory activity within the micromolar range (Table 1). The
benzhydroxamate 2 is a nanomolar HDAC8i but inhibits
HDAC6 more potently. Compounds 3 and 10 were
reported as nanomolar HDAC8i. HDAC8 exhibits weaker
binding affinities for known pan-HDAC inhibitors, such
as suberoylanilide hydroxamic acid (SAHA) and TSA
(Figure 4B).
Clinically, isoform-specific or selective HDAC8i are like-
ly to be relevant in treatment of T cell leukemia and in
neuroblastoma, where HDAC8 is the only correlated
HDAC. It remains to be seen whether inhibition of one
HDAC isoform can minimize adverse effects (such as diar-
rhea, and hematological and cardiac toxicities) as seen in
patients treated with pan-HDAC inhibitors, such as
SAHA. However, the functional redundancy of the other
class I isoforms or shared targets might mask the selective
profile of such inhibitors. For example, while PCI-34051
seems to have already excellent potency and selectivity,
further selective HDAC8 inhibitors with different scaffolds
are necessary for advanced preclinical evaluation. This is
necessary to distinguish between HDAC8-related-specific
versus compound-specific efficacy and safety. Further po-
tent and selective inhibitors would also clarify whether the
inhibition profiles obtained with pure HDAC isotypes are
mirrored in vivo using distinct hyperacetylation substrates
or mass spectrometric evaluation. It has been shown that
IC50 values of HDAC inhibitors differ if one uses either
recombinant subtypes or HDACs in a more native setup
(e.g., complexes) [83].HDAC8 has high flexibility and, hence, is able to accom-
modate a range of diverse inhibitors, exemplified by the
29 X-ray human HDAC8 structures in the Protein Data
Bank (PDB, http://www.wwpdb.org/) (Figure 4B). In addi-
tion to acetyl-lysine-containing peptidic substrates, a vari-
ety of pan-HDACi have been co-crystallized with HDAC8,
including SAHA, TSA, M344, CRA19156, aroyl pyrrole
hydroxy amide (APHA), PTSB-hydroxamate, and largazole
(Figure 4B, Table 2). The structures show the same archi-
tecture as other HDAC members (for a detailed review, see
[84,85]) (Figure 5A,B). The zinc ion is coordinated by D178,
D267, and H180. The remaining two sites are occupied by
zinc-binding groups of the inhibitors or the inhibitor and
one water molecule. The active site tunnel comprises lipo-
philic amino acids. Notably, two phenylalanines (F152 and
F208) contribute strongly to formation of the tunnel. The
rim of the tunnel is formed by several loop regions (named
L1–L4) of variable sizes and conformations that differ
among HDAC isoforms. Analysis of the HDAC8 structures
revealed several conformations of the L1 (from S30 to K36)
and L2 (P91 to T105) loops (Figure 5A). Both are not always
resolved in the X-ray structures, indicating an increased
flexibility. L1 has been shown to adopt two different con-
formations (colored blue and magenta in Figure 5A), which
dramatically change the size of the binding pocket. Given
the flexibility of L1 and L2, the crystallized inhibitors TSA,
APHA, and PTSB-hydroxamate occupy different areas at
the rim of the active site.
Recently, the structure of smHDAC8 was solved, in apo
and inhibited forms (Table 2). Using HDAC-biased chemi-
cal scaffolds, initial hits were quickly discovered for
smHDAC8 [68,86]. The structure of smHDAC8 is similar
to that of hHDAC8, but active-site differences were recog-
nized in the primary structure [e.g., human methionine
hM274 is a histidine (smH292) in S. mansoni].
First hits were the pan-HDAC inhibitors SAHA and
M344 (Figure 4B) [24]. A structural change was observed,
at least in the apo and SAHA-bound smHDAC8 structures,
in the side chain of a conserved active-site phenylalanine487
Table 2. Inhibitors or substrates co-crystallized with HDAC8
PDB ID HDAC8 Inhibitor Substrate Form Res. Year Refs
1T64 Human TSA WT 1.90 2004 [11]
1T67 Human M344 WT 2.31 2004 [11]
1T69 Human SAHA WT 2.91 2004 [11]
1VKG Human CRA19156 WT 2.20 2004 [11]
1W22 Human PTSB-hydroxamate WT 2.50 2004 [45]
2V5W Human – Acetylpeptide Y306F 2.00 2007 [39]
2V5X Human Hydroxamate S39D 2.25 2007 [39]
3EW8 Human M344 D101L 1.80 2008 [96]
3EWF Human – Acetylpeptide H143A 2.50 2008 [96]
3EZP Human M344 D101N 2.65 2008 [96]
3EZT Human M344 D101E 2.85 2008 [96]
3FO6 Human M344 D101A 2.55 2008 [96]
3F07 Human APHA WT 3.30 2008 [96]
3F0R Human TSA WT 2.54 2008 [96]
3MZ3 Human M344 WT/Co2+ 3.20 2010 [97]
3MZ4 Human M344 D101L/Mn2+ 1.85 2010 [97]
3MZ6 human M344 D101L/Fe2+ 2.00 2010 [97]
3MZ7 human M344 D101L/Co2+ 1.90 2010 [97]
3SFF human Amino acid derivative WT 2.00 2011 [82]
3SFH human Amino acid derivative WT 2.70 2011 [82]
3RQD human Largazole thiol WT 2.14 2011 [98]
4BZ5 S. mansoni – WT apoa 1.78 2013 [24]
4BZ6 S. mansoni SAHA WT 2.00 2013 [24]
4BZ7 S. mansoni M344 WT 1.65 2013 [24]
4BZ8 S. mansoni J1038 WT 2.21 2013 [24]
4BZ9 S. mansoni J1075 WT 2.00 2013 [24]
4CQF S. mansoni Mercaptoacetamide WT 2.30 2014 [87]
4QA0 human SAHA C153F 2.24 2014 [74]
4QA1 human M344 A188T 1.92 2014 [74]
4QA2 human SAHA I243N 2.38 2014 [74]
4QA3 Human TSA T311M 2.88 2014 [74]
4QA4 human M344 H344R 1.98 2014 [74]
4QA5 human – Acetylpeptide A188T/Y306F 1.76 2014 [74]
4QA6 human – Acetylpeptide I243N/Y306F 2.05 2014 [74]
4QA7 human – Acetylpeptide H334R/Y306F 2.31 2014 [74]
aApo-structure without inhibitor, listed for comparison.
Review Trends in Pharmacological Sciences July 2015, Vol. 36, No. 7(hF152, smF151). The smF151 side chain is inserted in a
hydrophobic pocket, away from the active site of the en-
zyme (flipped-out conformation) (Figure 5C). By contrast,
in hHDAC8 (and in all other hHDACs whose structure has
been solved), this residue is locked in a conformation
(flipped-in), where it participates in the formation of the
active-site pocket [24]. This structural difference is due to
sequence and structural changes observed in loops sur-
rounding the HDAC8 active site. Binding of M344 to
smHDAC8 induced a flipping-in of smF151, showing that
the side chain of this phenylalanine can freely change the
conformation even if the flipped-out conformation appears
preferred [24].
Virtual screening using these structural data enabled
the identification of new linker-less, hydroxamate-based
inhibitors of smHDAC8. Among them, J1038 and J1075
(Figure 4B) led to structural data in complex with
smHDAC8 [24]. The two inhibitors used different specific
features of the smHDAC8 active site (Figure 5D,E). J1038
not only interacts specifically through a salt bridge with
the side chain of smH292, but also induces a flipping-in of488smF151 (Figure 5D). By contrast, J1075 does not interact
with smH292, but forces smF151 into its flipped-out con-
formation (Figure 5E). Also, a tyrosine residue, smY341,
attains an intermediate conformation between those ob-
served in the apo and inhibitor-bound forms of smHDAC8,
thus preventing this residue interacting with the hydro-
xamate group of the inhibitor. Despite the bulkiness of
these inhibitors, the IC50 values were similar for both
smHDAC8 and hHDAC8 (Table 1), whereas pan-HDAC
inhibitors, such as SAHA and M344, are more potent on
other hHDACs (200–500 times on hHDAC1, 100–150 times
on hHDAC3, and 50–200 times on hHDAC6; Table 1) [24].
In a second study, an inhibitor bearing a mercaptoace-
tamide (1a) warhead (Figure 4B) showed specificity for
smHDAC8 over hHDAC8 (Table 1) [87]. The structure in
complex with smHDAC8 revealed a specific binding mode
of its warhead to the catalytic zinc and a flipping-in of the
smF151 side chain, whereas smH292 was not involved in
inhibitor binding (Figure 5F) [87]. Both linkerless hydro-
xamates and mercaptoacetamide induced apoptosis in cul-
tured worms.
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Figure 5. Structural specificities for inhibition of human and Schistosoma mansoni histone deactylase 8 (HDAC8). (A) Superimposition of all human HDAC8 structures from
the Protein Data Bank (PDB). Only the protein backbone is shown as a white ribbon. The two main clusters of the flexible loop L1 are colored dark blue and magenta,
respectively. In cases where the loop L1 is not fully resolved in the X-ray structures, it is colored cyan. Flexible loop L2 is colored orange. (B) Interaction of the inhibitor
SAHA (green) at the HDAC8-binding site (PDB ID 4QA2). The molecular surface of the binding pocket is displayed. Hydrogen bonds and metal interactions are shown as
broken lines. (C–F) Close-up view of the active site of S. mansoni HDAC8 (smHDAC8) with bound inhibitors: suberoylanilide hydroxamic acid (SAHA) (C), J1038 (D), J1075
(E), and 1a (mercaptoacetamide) (F) [24,87]. The secondary structure elements of smHDAC8 are shown as light-brown ribbons. Important smHDAC8 active site side chains
and inhibitors are shown as sticks and are labeled. Carbons are shown in gray (smHDAC8) and green (inhibitors), nitrogens in blue, and oxygens in red. Hydrogen and
coordination bonds are shown as broken lines.
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HDAC8 has emerged as an attractive target for isotype-
selective drug development in a variety of diseases, such
as cancer, parasitic and viral infections, as well as
neurodegenerative diseases. Despite promising initial
target validation and pharmacological intervention stud-
ies, many questions remain. New nonhistone substrates
are still being discovered [88], and the function ofHDAC8 in normal physiology has to be defined further.
A recent example is a role of HDAC8 in bone differenti-
ation [84], which may also open up a new therapeutic
area. Data on different subcellular locations (nuclear
versus cytoplasmic) of HDAC8 [43,89] implicate a con-
text-dependent action of its inhibitors and may help to
define specific disease subsets, such as in cancer, for
treatment.489
Review Trends in Pharmacological Sciences July 2015, Vol. 36, No. 7It has been shown that HDAC8 can be targeted selec-
tively and available HDAC8–inhibitor structures will aid
future development immensely. However, the demonstrat-
ed flexibility of HDAC8 may yet make such approaches
difficult, especially in the design of species-selective inhi-
bitors. For selectivity on the human isotype versus
smHDAC8, differences in the active site (see above) pave
a clear path towards selective inhibitors; however, for use
in humans, the lack of structural data especially on
HDAC6 makes rational optimization of selectivity towards
that subtype difficult. HDAC inhibitors have already
shown promise for treatment of apicomplexan diseases,
such as malaria (caused by Plasmodium spp.) or trypano-
somiasis [90–92]. Structure-based studies on smHDAC8
inhibitors may be considered a model approach for species-
selective inhibitors in such diseases [24,87] and may also
extend to, for example, fungi [93]. For antiviral therapy,
preclinical tests of specific HDAC8 inhibitors will provide
valuable insight into its druggability in this context. For
infectious diseases, the role of HDAC8 in the immune
response by repressing interleukin b gene expression
[94] or in the toxin-induced resistance of macrophages
[95], has to be considered.
Thus, HDAC8 remains not only a multifaceted and
challenging, but also a promising target for pharmacologi-
cal intervention.
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